Mylan defeats Sanofi’s claims it illegally prevented competition to EpiPen

Ben Remaly

02 February 2021

iStock/smartstock

Sanofi-Aventis failed to demonstrate that Mylan monopolised the market for epinephrine auto-injectors used to treat severe allergic reactions, a Kansas federal court ruled in a recently unsealed opinion.

Subscribe to Global Competition Review

Subscribe to unlock unlimited access

Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.

Subscribe now

Already have access? Login below

Ben Remaly

View full biography

Author | Editor, GCR USA

[email protected]

Tipline

Up in smoke: The Tipline for 3 October 2022
For the better part of two years, the Federal Trade Commission litigated against an agreement between Altria and Juul not to compete against each other in the market for vape cigarettes. The commission lost before its administrative tribunal, but perhaps can count a win in the end. In shades of AT&T selling off its Time Warner assets, the Marlboro maker is ditching the terms of its noncompete with Juul as the latter struggles to …
Heavens to Betsy: The Tipline for 30 September 2022
Take the bitter with the sweet: The Tipline for 29 September 2022

Mylan defeats Sanofi’s claims it illegally prevented competition to EpiPen

Subscribe to Global Competition Review

Subscribe to unlock unlimited access

Already have access? Login below

Related Topics

Ben Remaly